Skin irritation and itching, often intense, are common consequences of mosquito bites. Interest in cosmetics formulated with natural ingredients has markedly increased among consumers, perceiving them as healthier, safer and more sustainable. We developed a natural formulation based on botanical ingredients for the treatment of mosquito bites. In this work, we tested the physicochemical and microbiological stability of this novel formulation, as well as its skin tolerance. Moreover, we performed an in vitro test to assess its soothing efficacy in comparison with an ammonia-based product. According to our findings, the natural formulation resulted in a stable oil-in-water emulsion, with an appealing texture and good skin tolerance; no cases of erythema or edema were observed in any of the volunteers with sensitive skin after product application. In addition, an in vitro test performed on a keratinocytes cell line showed that our formulation significantly reduced IL-1α levels, with a displayed efficacy comparable to the ammonia-based product. This study emphasizes the promising potential of botanical ingredients in the field of cosmetic dermatology, offering high-performance, well-tolerated skincare products suitable for the treatment of common skin irritations, such as mosquito bites.

Background: Hair loss is a multifactorial condition influenced by aging, oxidative stress, hormonal regulation, and nutritional status. Nutraceutical supplementation has emerged as a potential strategy to support hair follicle function. This study evaluated the clinical efficacy of a nutraceutical ingredient (Kyoh®) at two concentrations versus placebo in individuals with hair loss. Methods: A randomized, parallel-group study was conducted in 150 volunteers aged 30–60 years. Participants received a high-dose (Kyoh BB-01), low-dose (Kyoh BB-02), or placebo (Kyoh BB-03) for 84 days. Hair parameters were assessed by digital trichoscopy at baseline, day 56, and day 84. Endpoints included hair density, follicular unit density, hair diameter, and hairs per follicular unit. Hair shedding was evaluated by comb test, and subjective perception by questionnaires. Results: The high-dose group showed significant increases in hair density and follicular unit density at days 56 and 84, as well as higher hairs per follicular unit at day 84. The low-dose group also improved these parameters to a lesser extent. No significant changes were observed in the placebo group. Hair diameter and shedding remained unchanged. Subjective results supported instrumental findings. Conclusion: The nutraceutical improved key hair growth parameters, with greater efficacy at higher dose.

Background/Objectives: Conventional psychometric instruments generally show limited ability to correlate with circulating biological markers. ADNe® is a 29-item psychogenic instrument based on a neurotransmitter-weighted response framework, designed to model functional patterns of neurobiological activation rather than classify personality traits. This study aimed to explore whether ADNe® neurofactor scores are associated with plasma concentrations of cortisol, interleukin-6 (IL-6), and testosterone in healthy adults. Methods: Twenty healthy volunteers (15 women, 5 men; mean age 30.3 ± 9.6 years, range 22–61) completed the ADNe® questionnaire and provided a peripheral blood sample on the same day. Plasma was isolated by centrifugation (400 × g, 5 min), and biomarker levels were quantified using ELISA. Statistical analyses included Spearman rank correlations and exploratory multiple linear regression models using the seven neurofactors as simultaneous predictors. Results: Significant associations were identified between selected neurofactors and biomarkers. Sm (attentional amplitude) showed an inverse correlation with testosterone (ρ = −0.567; p = 0.022), while Mn (strategic acuity) was inversely associated with IL-6 (ρ = −0.489; p = 0.046). Exploratory multivariate models showed high apparent explanatory capacity within this dataset (R² = 0.848 for IL-6, 0.735 for testosterone, and 0.569 for cortisol). However, given the small sample size and the number of predictors included, these estimates should be interpreted with caution. Conclusions: In this pilot study, ADNe® neurofactor profiles showed associations with circulating biomarkers, suggesting that this approach may capture dimensions related to physiological regulation. Nevertheless, the findings are exploratory and may be influenced by overfitting and unmeasured confounding variables. Independent replication in larger, pre-registered studies with appropriate validation strategies will be necessary to confirm the robustness and generalizability of these results.

This translational study compared the efficacy and onset of action of avvera™ oral collagen peptides versus an active control in improving key skin parameters. For in vitro experiments, normal human dermal fibroblasts (NHDF) were exposed to avvera™ or the active control and secreted pro-collagen I was quantified by ELISA. For in vivo assays, a clinical study conducted on 67 healthy women assessed hydration (Corneometer), barrier function/TEWL (Tewameter), and crow’s-feet wrinkle area and length (standardized 3D imaging) at baseline, day 28, and day 56. In vitro, NHDF exposed for 72 h to the corresponding peptide preparations showed similar increased pro-collagen I secretion, but a larger increase was elicited by avvera™, indicating a stronger pro-collagen-stimulating effect. The in vivo assays showed that both products improved hydration (≈ +29-43%) and reduced TEWL by day 56 (≈ −8-9%). In addition, both products reduced wrinkle area and length, but avvera™ produced significantly greater reductions at day 28 than the active control, conferring an early advantage. These findings link fibroblast activity with short-term clinical improvements, support the biological benefits of oral collagen peptides, and show that avvera™ has a dual action (enhancing skin hydration and barrier function) for greater early and faster visible skin benefits.